Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Aerovate Therapeutics Inc...

    NASDAQ: AVTE · Real-Time Price · USD
    2.68
    0.00 (0.00%)
    At close: Apr 28, 2025, 3:59 PM

    Aerovate Therapeutics Statistics

    Share Statistics

    Aerovate Therapeutics has 28.98M shares outstanding. The number of shares has increased by 0.56% in one year.

    Shares Outstanding

    n/a
    		 28.98M

    Shares Change (YoY)

    n/a
    		 0.56%

    Shares Change (QoQ)

    n/a
    		 0.38%

    Owned by Institutions (%)

    n/a
    		 99.99%

    Shares Floating

    n/a
    		 n/a

    Failed to Deliver (FTD) Shares

    n/a
    		 17,337

    FTD / Avg. Volume

    n/a
    		 216.9%

    Short Selling Information

    The latest short interest is 4.59M, so 15.85% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 4.59M

    Short % of Shares Out

    n/a
    		 15.85%

    Short % of Float

    n/a
    		 40.12%

    Short Ratio (days to cover)

    n/a
    		 16.61

    Valuation Ratios

    The PE ratio is -38.07 and the forward PE ratio is -3.39. Aerovate Therapeutics's PEG ratio is 2.54.

    PE Ratio

    n/a
    		 -38.07

    Forward PE

    n/a
    		 -3.39

    PS Ratio

    n/a
    		 0

    Forward PS

    n/a
    		 3.4

    PB Ratio

    n/a
    		 34.68

    P/FCF Ratio

    n/a
    		 -37.23

    PEG Ratio

    n/a
    		 2.54
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Aerovate Therapeutics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 20.93, with a Debt / Equity ratio of 0.01.

    Current Ratio

    n/a
    		 20.93

    Quick Ratio

    n/a
    		 20.93

    Debt / Equity

    n/a
    		 0.01

    Debt / EBITDA

    n/a
    		 -0.01

    Debt / FCF

    n/a
    		 -0.01

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 n/a

    Profits Per Employee

    n/a
    		 $-17,407,000

    Employee Count

    n/a
    		 4

    Asset Turnover

    n/a
    		 0

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 55K

    Effective Tax Rate

    n/a
    		 -0.08%

    Stock Price Statistics

    The stock price has increased by -99.64% in the last 52 weeks. The beta is 0.95, so Aerovate Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 0.95

    52-Week Price Change

    n/a
    		 -99.64%

    50-Day Moving Average

    n/a
    		 88.53

    200-Day Moving Average

    n/a
    		 81.25

    Relative Strength Index (RSI)

    n/a
    		 58.33

    Average Volume (20 Days)

    n/a
    		 7,993

    Income Statement

    Revenue

    n/a
    		 n/a

    Gross Profit

    n/a
    		 n/a

    Operating Income

    n/a
    		 -74.6M

    Net Income

    n/a
    		 -69.63M

    EBITDA

    n/a
    		 -74.31M

    EBIT

    n/a
    		 -74.6M

    Earnings Per Share (EPS)

    n/a
    		 -2.44
    Full Income Statement

    Balance Sheet

    The company has 33.75M in cash and 417K in debt, giving a net cash position of 33.33M.

    Cash & Cash Equivalents

    n/a
    		 33.75M

    Total Debt

    n/a
    		 417K

    Net Cash

    n/a
    		 33.33M

    Retained Earnings

    n/a
    		 -233.05M

    Total Assets

    n/a
    		 77.53M

    Working Capital

    n/a
    		 74.96M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -71.2M and capital expenditures 0, giving a free cash flow of -71.2M.

    Operating Cash Flow

    n/a
    		 -71.2M

    Capital Expenditures

    n/a
    		 n/a

    Free Cash Flow

    n/a
    		 -71.2M

    FCF Per Share

    n/a
    		 -2.49
    Full Cash Flow Statement

    Margins

    Gross Margin

    n/a
    		 n/a

    Operating Margin

    n/a
    		 n/a

    Pretax Margin

    n/a
    		 n/a

    Profit Margin

    n/a
    		 n/a

    EBITDA Margin

    n/a
    		 n/a

    EBIT Margin

    n/a
    		 n/a

    FCF Margin

    n/a
    		 n/a

    Dividends & Yields

    AVTE does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for AVTE is $70, which is 2511.9% higher than the current price. The consensus rating is "Hold".

    Price Target

    n/a
    		 $70

    Price Target Difference

    n/a
    		 2511.9%

    Analyst Consensus

    n/a
    		 Hold

    Analyst Count

    n/a
    		 7
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Stock Splits

    The last stock split was on Apr 29, 2025. It was a backward split with a ratio of 1:35.

    Last Split Date

    n/a
    		 Apr 29, 2025

    Split Type

    n/a
    		 backward

    Split Ratio

    n/a
    		 1:35

    Scores

    Altman Z-Score

    n/a
    		 13.38

    Piotroski F-Score

    n/a
    		 1

    Add to Watchlist